GYKI 52466 has positive modulatory effects on AMPA receptors

Brain Res. 2001 Feb 23;892(2):396-400. doi: 10.1016/s0006-8993(00)03323-0.

Abstract

The 2,3-benzodiazepine derivative GYKI 52466 has been well characterized as a negative modulator of AMPA-type glutamate receptors. The present study re-examined the effects of GYKI 52466 on AMPA receptor-mediated currents in patches excised from pyramidal neurons in the hippocampal CA1 field and found that this drug has positive modulatory effects in addition to its receptor blocking action. A low concentration of GYKI 52466 (10 microM) reliably increased the steady-state current by about three-fold, while the peak current was reduced by 30% only. Higher drug concentrations produced parallel reductions in both the steady-state and peak currents. The increase in the steady-state current was not accompanied by a change in the deactivation time constant and thus, is more likely to result from a change in desensitization than a slowing of channel closing. The results indicate that GYKI 52466 modulates AMPA receptor-mediated currents in a complex manner, perhaps by acting through more than one binding site.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Anti-Anxiety Agents / pharmacology*
  • Benzodiazepines*
  • Electrophysiology
  • Hippocampus / cytology
  • Hippocampus / drug effects
  • Kinetics
  • Male
  • Patch-Clamp Techniques
  • Pyramidal Cells / drug effects
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, AMPA / drug effects*

Substances

  • Anti-Anxiety Agents
  • Receptors, AMPA
  • GYKI 52466
  • Benzodiazepines